The long-term goal of this research is to understand the chemical, biochemical, and biological aspects of thyroid hormone and its bioactive metabolites such that safer and more effective therapeutic agents can be developed that act at targets of the thyroid hormone endocrine system. We recently discovered a novel class of endogenous compounds called thyronamines that are chemical derivatives of thyroxine (T4). 3- Iodothyronamine (T1AM), the most active member identified to date of this class, has no affinity for the nuclear thyroid hormone receptors TR1 and TR2, but nevertheless has unique and potentially therapeutically useful biological actions. Single doses of T1AM rapidly induce hypothermia, bradycardia, and hyperglycemia in rodents. In addition, T1AM induces a profound fueling shift away from carbohydrates and toward fat burning in Siberian hamsters, a hibernating rodent, as well as mice. We recently demonstrated that chronic administration of low doses of T1AM inhibit feeding behavior in obese mice;i.e. like leptin, T1AM appears to act as an endogenous anorectic agent. In rodents and humans endogenous T1AM is found in circulation and tissues at levels that are similar to that of T3, one of the principle bioactive metabolites of T4. Similarly to T4, circulating T1AM is tightly bound to serum binding proteins and these binding proteins are different from those used to transport T4. In human serum, T1AM binds specifically to apoB-100, the primary lipoprotein of low density lipoprotein (LDL) particles, suggesting a potential role of T1AM in modulating cholesterol homeostasis. T1AM has very unusual pharmacokinetic properties for a biogenic primary phenethylamine. The plasma half- life of T1AM is 5.5 hr in mice whereas half-lives of 1-2 min are the norm for chemically similar biogenic amines such as serotonin and dopamine. In addition, the volume of distribution of T1AM is very high suggesting that T1AM distributes widely from circulation into all tissues including poorly perfused tissues such as fat and muscle. Further consistent with this is the finding that T1AM is robustly transported into a variety of cell types, including cells derived from fat and skeletal muscle, and this transport is mechanism is highly selective for T1AM and occurs by a mechanism that does not involve a member of the biogenic amine reuptake transporter family. Understanding these unusual biochemical properties of T1AM and the underlying physiology they reveal is the direct goal of this grant proposal. The research plan is comprised of the following Specific Aims: (1) . Isolate and Characterize T1AM binding proteins in mouse and rat serum;(2) Determine whether T1AM affects cholesterol uptake and metabolism in vivo;(3) Discover and characterize conjugated metabolites of T1AM.;(4) Determine the mechanism of intracellular uptake of T1AM and search for T1AM target proteins.

Public Health Relevance

Thyroid hormone has important actions for maintaining health in both children and adults. These actions must be in balance as both over-and under-abundance of thyroid hormone can result in serious disorders and disease. The primary form of thyroid hormone made in the thyroid gland is thyroxin, which is metabolized into other biologically active products such as iodothyronines and thyronamines. The purpose of this research is to understand the actions of thyronamines at the molecular, cellular, and tissue level such that safer and more effective therapeutic agents that target the actions of thyroid hormone can be developed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK091539-02
Application #
8464697
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Margolis, Ronald N
Project Start
2012-05-01
Project End
2016-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
2
Fiscal Year
2013
Total Cost
$323,228
Indirect Cost
$113,340
Name
Oregon Health and Science University
Department
Physiology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Fernando, Roshini; Placzek, Ekaterina; Reese, Edmund A et al. (2017) Elevated Serum Tetrac in Graves Disease: Potential Pathogenic Role in Thyroid-Associated Ophthalmopathy. J Clin Endocrinol Metab 102:776-785
Devereaux, Jordan; Ferrara, Skylar J; Banerji, Tania et al. (2016) Increasing Thyromimetic Potency through Halogen Substitution. ChemMedChem 11:2459-2465
Placzek, Andrew T; Scanlan, Thomas S (2015) New synthetic routes to thyroid hormone analogs: d6-sobetirome, 3H-sobetirome, and the antagonist NH-3. Tetrahedron 71:5946-5951
Hackenmueller, Sarah A; Scanlan, Thomas S (2012) Identification and quantification of 3-iodothyronamine metabolites in mouse serum using liquid chromatography-tandem mass spectrometry. J Chromatogr A 1256:89-97
Roy, Gouriprassana; Placzek, Ekaterina; Scanlan, Thomas S (2012) ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation. J Biol Chem 287:1790-800